Business
Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer
Dr. Swaminathan will be responsible for establishing and leading business development, leveraging his expertise in licensing, transactions, and establishing
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":"\n\nDr. Swaminathan will be responsible for establishing and leading business development, leveraging his expertise in licensing, transactions, and establishing strategic collaborations within the biotechnology and pharmaceutical industries.\n\n\nIn his two prior companies serving as Chief Business Officer, Dr. Swaminathan demonstrated strong deal making ability - At Alteogen, he executed $3.8 billion and $1.4 billion deals with two top ten global pharmaceutical companies, increasing the value of the company approximately 10-fold, from $400 million to $4 billion.\n\n\nAt Actinium, within a year of his hiring, he executed the largest deal in their history, worth $452 million for commercial rights of EU, ME and North Africa.\n\n\n HOUSTON--(BUSINESS WIRE)--\nCoya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced the appointment of Arun Swaminathan, Ph.D. to the role of Chief Business Officer. In this role, Arun will be responsible for facilitating new business development partnerships, including in/out licensing opportunities, across the Company’s pipeline.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230327005218/en/Arun Swaminathan, Ph.D., Chief Business Officer, Coya Therapeutics, Inc.\nDr. Swaminathan comes to Coya with over 20 years of hands-on healthcare business executive experience with an emphasis on corporate and business development, strategy, and finance. He possesses a demonstrated history of prospecting, evaluating, structuring, and closing company validating transactions\n\n“Our team is excited to welcome Arun to Coya at such an exciting time in our evolution. We look forward to working with him as we leverage his extensive experience and successful track record in corporate strategy and business development,” said Howard H. Berman, Ph.D., Chief Executive Officer. “This is an opportune time for Arun to join our team on the heels of recent positive data and as we accelerate the clinical development of our biologic and cell therapy Treg immunomodulatory assets. We are confident that Arun’s contributions will prove to be impactful for Coya and our shareholders.”\n\n“Coya has ...